Gastrointestinal Cancers NCCN Guidelines: Esophageal and Esophagogastric Junction Cancers, Version 2.2023
Gastrointestinal Cancers Rapid Changes in Colorectal Cancer Statistics: American Cancer Society Report
Gastrointestinal Cancers ASCO GI 2023: Zolbetuximab Plus mFOLFOX6 For Certain Patients With Advanced Gastric Cancers
Gastrointestinal Cancers ASCO 2022: Dostarlimab-gxly in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Gastrointestinal Cancers ASCO 2022: Nimotuzumab Plus Gemcitabine for KRAS Wild-Type Pancreatic Cancer
Gastrointestinal Cancers ASCO 2022: Panitumumab Plus mFOLFOX6 for Certain Patients With Metastatic Colorectal Cancer
Gastrointestinal Cancers Pembrolizumab/Trametinib vs Gemcitabine in Addition to SBRT for Pancreatic Cancer
Gastrointestinal Cancers Immunotherapy Doublet in Patients With MSI-H/dMMR Metastatic Colorectal Cancer
Gastrointestinal Cancers Addition of Pembrolizumab to Trastuzumab and Chemotherapy in Previously Untreated Patients With Advanced HER2-Positive Gastric Adenocarcinoma
Gastrointestinal Cancers Combination Anti–PD-L1 and Anti–CTLA-4 Immunotherapy in Advanced Liver Cancer
Gastrointestinal Cancers Nivolumab Combination Regimens in Previously Untreated Patients With Advanced Esophageal Squamous Cell Carcinoma
Gastrointestinal Cancers TOPAZ-1 Trial: Durvalumab and Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Gastrointestinal Cancers First-Line Nivolumab Plus Oxaliplatin-Based Chemotherapy for HER2-Negative, Unresectable, Advanced or Recurrent Gastric Cancers
